Technologies
PDF


WARF: P160032US01

  • Assigned to WARF as biological material.

New Influenza B Virus Enables Real-Time Tracking of Disease Progression


INVENTORS -

Andrew Mehle

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new influenza B reporter virus for measuring viral replication in culture and in vivo imaging of infected animals.
OVERVIEWInfluenza infections in humans, from the common seasonal flu to the deadly pandemics of the 20th century, are caused chiefly by influenza A and influenza B viruses. Understanding the in vivo dynamics of viral infection could lead to improved ways of treating or preventing influenza, but existing models relied on proxies to measure viral replication or on analyses performed after the animal model was sacrificed. It was not possible to follow viral load and spread throughout the course of infection in the same animal.

Then, a UW–Madison researcher developed an influenza A reporter virus with the NanoLuc (NLuc) luciferase reporter gene. The reporter virus has been used in bioluminescent imaging to track infections in real time in infected mice and ferrets. Because this approach is non-invasive, it enables serial observations of viral load and dissemination in animals, even following clearance of a sublethal challenge. However, an equivalent reporter virus for influenza B has not been available, until now.
THE INVENTIONThe UW–Madison researcher extended his earlier technology and developed a novel, fully replication competent influenza B reporter virus. It is useful for fast and quantitative measures of viral replication in culture as well as tracking disease progression in infected animals. Importantly, while the present technology is directed at influenza B, the approach is adaptable to any strain of influenza A or B.

The virus stably maintains the NLuc reporter gene, replicates with near-wild type kinetics in culture and is suitable for in vivo imaging of infected mice. Unlike currently available influenza B models, it is high throughput, does not use laborious culture-based assays to detect viral dissemination and load and does not require sacrificing animals.
APPLICATIONS
  • Understanding the progression and ecology of influenza B infection
  • Studying influenza dynamics
  • Rapidly assessing the effects of therapeutic interventions for influenza B
KEY BENEFITS
  • Allows real-time, in vivo imaging of disease progression in living animals
  • Maintains viral pathogenicity
  • High throughput
  • Can be used to more quickly determine the amount of infectious influenza virus
  • Can be expanded to other strains of influenza B virus
  • Enables fast and quantitative measures of viral replication in culture
STAGE OF DEVELOPMENTThis technology has successfully been used to visualize influenza B virus infection in vivo and monitor local and potentially systemic viral spread.
ADDITIONAL INFORMATION
For More Information About the Inventors
Publications
  • Mehle A. 2015. Fiat Luc: Bioluminescence Imaging Reveals In Vivo Viral Replication Dynamics. PLoS Pathog. 11, e1005081.
  • Karlsson E.A., Meliopoulus V.A., Savage C., Livingston B., Mehle A. and Schultz-Cherry S. 2015. Visualizing Real-Time Influenza Virus Infection, Transmission and Protection in Ferrets. Nat. Commun. 6.
  • Tran V., Moser L.A., Poole D.S. and Mehle A. 2013. Highly Sensitive Real-Time In Vivo Imaging of an Influenza Reporter Virus Reveals Dynamics of Replication and Spread. J. Virol. 87, 13321-13329.
Contact Information
For current licensing status, please contact Joshua Carson at jcarson@warf.org or 608-960-9844.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.